var data={"title":"Desmopressin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Desmopressin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5992?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=desmopressin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Desmopressin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=desmopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Desmopressin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51112251\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hyponatremia (Noctiva nasal spray):</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Desmopressin can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death. Desmopressin is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. Ensure serum sodium concentrations are normal before starting or resuming desmopressin. Measure serum sodium within 7 days and ~1 month after initiating therapy or increasing the dose and periodically during treatment. More frequently monitor serum sodium in patients &ge;65 years of age and in patients at increased risk of hyponatremia. If hyponatremia occurs, desmopressin may need to be temporarily or permanently discontinued.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157823\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>DDAVP;</li>\n      <li>DDAVP Rhinal Tube;</li>\n      <li>Noctiva;</li>\n      <li>Stimate</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157824\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>DDAVP;</li>\n      <li>DDAVP Melt;</li>\n      <li>DDAVP Rhinyle;</li>\n      <li>Nocdurna;</li>\n      <li>Octostim</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157868\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antihemophilic Agent;</li>\n      <li>\n        Hemostatic Agent;</li>\n      <li>\n        Hormone, Posterior Pituitary;</li>\n      <li>\n        Vasopressin Analog, Synthetic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157828\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes insipidus: Note:</b> Fluid restriction should be observed. Dosing should be individualized to response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV, SubQ:</i> US labeling: 2 to 4 mcg daily (0.5 to 1 mL) in 2 divided doses or one-tenth (<sup>1</sup>/<sub>10</sub>) of the maintenance intranasal dose. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IM, IV, SubQ:</i> Canadian labeling (DDAVP Injection only): 1 to 4 mcg (0.25 to 1 mL) once daily or one-tenth (<sup>1</sup>/<sub>10</sub>) of the maintenance intranasal dose. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal (100 mcg/mL nasal solution):</i> Usual dose range: 10 to 40 mcg daily (0.1 to 0.4 mL) as a single dose or divided 2 to 3 times daily; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover. Most adults require 10 mcg (0.1 mL) twice daily. <b>Note:</b> The nasal spray pump can only deliver doses of 10 mcg (0.1 mL) or multiples of 10 mcg (0.1 mL); if doses other than this are needed, the rhinal tube delivery system is preferred. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">US labeling: Initial: 0.05 mg twice daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (range: 0.1 to 1.2 mg divided 2 to 3 times daily). Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian labeling: Initial: 0.1 mg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (maximum: 1.2 mg/day in 3 divided doses). Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual formulation [Canadian product]:</i> DDAVP Melt: Initial: 60 mcg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 120 to 720 mcg equally divided 2 or 3 times daily. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intracranial hemorrhage associated with certain antiplatelet agents (aspirin, clopidogrel, prasugrel, ticlopidine, ticagrelor, cangrelor) (off-label use): </b>\n      <i>IV:</i> 0.4 mcg/kg once (NCS/SCCM [Frontera 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nocturia:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal: </i>Noctiva:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Not at risk for hyponatremia:</i> 1.66 mcg in either nostril ~30 minutes before bedtime.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>At risk for hyponatremia: </i>Initial: 0.83 mcg in either nostril ~30 minutes before bedtime. After &ge;7 days, may increase to 1.66 mcg if needed (provided the serum sodium is within the normal range during treatment with the 0.83 mcg dose). <b>Note: </b> The 0.83 mcg dose did not meet all prespecified efficacy endpoints in clinical trials but may have a lower risk of hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual formulation [Canadian product]: </i>Nocdurna:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Females: 25 mcg once daily at bedtime. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Males: 50 mcg once daily at bedtime;<b> Note:</b> In males &ge;65 years, evaluate serum sodium within 4 to 8 days after initiation and at 1 month of treatment; discontinue therapy if sodium falls below normal range. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary nocturnal enuresis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i> Initial: 0.2 mg at bedtime; dose may be titrated up to 0.6 mg to achieve desired response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual formulation [Canadian product]:</i> DDAVP Melt: Initial: 120 mcg administered 1 hour before bedtime; if bedwetting occurs after 3 days increase dose by 120 mcg/day. Dose may be further titrated up to a maximum of 360 mcg/day to achieve desired response. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration. Treatment period is up to 3 months and then reassess with 1 week off treatment; if additional therapy is necessary, resume at same dosage prior to discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A and von Willebrand disease (type 1):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> 0.3 mcg/kg by slow infusion; may repeat dose if needed (based on clinical response and laboratory results); if used preoperatively, administer 30 minutes before procedure. A maximum IV dose of 20 mcg has been recommended (DDAVP injection Canadian product labeling 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal (using high concentration spray [1.5 mg/mL]):</i> &lt;50 kg: 150 mcg (1 spray in a single nostril); &ge;50 kg: 300 mcg (1 spray each nostril); repeat use is determined by the patient's clinical condition and laboratory work. If using preoperatively, administer 2 hours before surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uremic bleeding:</b> Octostim [Canadian product]: <i>IV:</i> 0.3 mcg/kg over 20 to 30 minutes (maximum dose: 20 mcg)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Uremic bleeding associated with acute or chronic renal failure (off-label use in US):</b> <i>IV:</i> 0.4 mcg/kg over 10 minutes (Watson 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prevention of surgical bleeding in patients with uremia (off-label use in US):</b> <i>IV:</i> 0.3 mcg/kg over 30 minutes (Mannucci 1983)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157850\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=desmopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Desmopressin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetes insipidus: Note:</b> Fluid restriction should be observed in these patients; younger patients more susceptible to plasma osmolality shifts and possible hyponatremia. Dosing should be individualized to response.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Parenteral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">US labeling: Children &ge;12 years and Adolescents: IV, SubQ: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternative recommendations (off-label): Infants and Children &lt;12 years: IV, SubQ: No definitive dosing available. Adult dosing should <b>not</b> be used in this age group; adverse events such as hyponatremia-induced seizures may occur. Dose should be reduced. Some have suggested an initial dosage range of 0.1 to 1 mcg daily in 1 or 2 divided doses (Cheetham 2002). Initiate at low dose and increase as necessary. Closely monitor serum sodium levels and urine output; fluid restriction is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian labeling (DDAVP Injection only): IM, IV, SubQ: Children and Adolescents: 0.4 mcg (0.1 mL) once daily or one-tenth (<sup>1</sup>/<sub>10</sub>) of the maintenance intranasal dose. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal (using 100 mcg/mL nasal solution):</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;3 months and Children &le;12 years: Usual dose range: 5 to 30 mcg daily (0.05 to 0.3 mL daily) as a single dose or divided 2 times daily; adjust morning and evening doses separately for an adequate diurnal rhythm of water turnover. <b>Note:</b> The nasal spray pump can only deliver doses of 10 mcg (0.1 mL) or multiples of 10 mcg (0.1 mL); if doses other than this are needed, the rhinal tube delivery system is preferred. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">US labeling: Children &ge;4 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Canadian labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: Initial: 0.1 mg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis (maximum: 1.2 mg/day in 3 divided doses). Divide daily doses so that the evening dose is 2 times higher than the morning or afternoon dose to ensure adequate antidiuresis during the night. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual formulation [Canadian product]:</i> DDAVP Melt:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children: Initial: 60 mcg 3 times daily; total daily dose should be increased or decreased as needed to obtain adequate antidiuresis. Usual maintenance: 120 to 720 mcg equally divided 2 to 3 times daily; divide daily doses so that the evening dose is 2 times higher than the morning or afternoon dose to ensure adequate antidiuresis during the night. Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Hemophilia A and von Willebrand disease (type 1):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>IV:</i> Infants &ge;3 months, Children, and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Adverse events such as hyponatremia-induced seizures have been reported especially in young children using this dosing regimen (Das 2005; Molnar 2005; Smith 1989; Thumfart 2005; Weinstein 1989). Fluid restriction and careful monitoring of serum sodium levels and urine output are necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Intranasal (using high concentration spray [1.5 mg/mL]):</i> Infants &ge;11 months, Children, and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>SubQ:</i> Infants &ge;3 months, Children, and Adolescents: Octostim [Canadian product]: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary nocturnal enuresis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Oral:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>US labeling:</i> Children &ge;6 years and Adolescents: Initial: 0.2 mg at bedtime. Dose may be titrated up to 0.6 mg to achieve desired response. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Canadian labeling:</i> Children &ge;5 years and Adolescents: Initial: 0.2 mg at bedtime; if bedwetting occurs after 3 days may increase dose by 0.2 mg/day up to a maximum of 0.6 mg/day. Fluid intake should be limited 1 hour prior to dose until the next morning, or at least 8 hours after administration. Treatment period is up to 3 months and then reassess with 1 week off treatment; if additional therapy is necessary, resume at same dosage prior to discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Sublingual [Canadian product]:</i> DDAVP Melt: Children &ge;5 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157829\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Nocturia:</b> <i>Intranasal: </i>Noctiva: Initial: 0.83 mcg in either nostril ~30 minutes before bedtime. After &ge;7 days, may increase to 1.66 mcg, if needed (provided the serum sodium is within the normal range during treatment with the 0.83 mcg dose). <b>Note: </b>The 0.83 mcg dose did not meet all prespecified efficacy endpoints in clinical trials but may have a lower risk of hyponatremia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2697324\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &ge;50 mL/minute: There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CrCl &lt;50 mL/minute: Use is contraindicated according to the manufacturer's labeling (except 1.5 mg/mL nasal spray); however, has been used in acute and chronic renal failure patients experiencing uremic bleeding or for prevention of surgical bleeding (off-label uses in US) (Mannucci 1983; Watson 1984).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15796022\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157804\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Emulsion, Nasal, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Noctiva: 0.83 mcg/0.1 mL (3.8 g); 1.66 mcg/0.1 mL (3.8 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 4 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 4 mcg/mL (10 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mcg/mL (1 mL, 10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as acetate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Nasal, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 0.01% (5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP Rhinal Tube: 0.01% (2.5 mL) [contains chlorobutanol (chlorobutol)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stimate: 1.5 mg/mL (2.5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.01% (2.5 mL, 5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as acetate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 0.1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">DDAVP: 0.1 mg [DSC], 0.2 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.1 mg, 0.2 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157789\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21005940\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:0em;\">DDAVP and Minirin 5 mL bottles contain 50 sprays.</p>\n    <p style=\"text-indent:0em;\">Stimate 2.5 mL bottles contain 25 sprays.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6705371\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Injection, as acetate [preservative free]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octostim: 15 mcg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, Nasal, as acetate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octostim: 1.5 mg/mL (2.5 mL) [contains benzalkonium chloride]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet, Sublingual, as acetate:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DDAVP Melt: 60 mcg, 120 mcg, 240 mcg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Nocdurna: 25 mcg, 50 mcg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157807\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IM (Canadian labeling [DDAVP Injection only]; not in US labeling), IV push, SubQ injection: Central diabetes insipidus: Withdraw dose from ampul into appropriate syringe size (eg, insulin syringe). Further dilution is not required. Administer as direct injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemophilia A, von Willebrand disease (type 1), and prevention of surgical bleeding in patients with uremia (off-label in US) (Mannucci 1983): Infuse over 15 to 30 minutes; Octostim [Canadian product]: Infuse over 20 to 30 minutes; infusion should not be less than 20 minutes. If used preoperatively, administer 30 minutes prior to procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute uremic bleeding (off-label in US) (Watson 1984a): May infuse over 10 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Uremic bleeding: Octostim [Canadian product]): Bleeding time should be normalized by administering a test dose once bleeding disorder is diagnosed or at least 72 hours prior to surgical procedures. Infuse over 20 to 30 minutes. When used pre-operatively administer 30 minutes prior to procedure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Intranasal: Ensure that nasal passages are intact, clean, and free of obstruction prior to administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DDAVP: Nasal pump spray: Delivers 0.1 mL (10 mcg); for doses &lt;10 mcg or for other doses which are not multiples, use rhinal tube. DDAVP Nasal spray delivers fifty 10 mcg doses. For 10 mcg dose, administer in one nostril. Any solution remaining after 50 doses should be discarded. Pump must be primed prior to first use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DDAVP Rhinal tube: Insert top of dropper into tube (arrow marked end) in downward position. Squeeze dropper until solution reaches desired calibration mark. Disconnect dropper. Grasp the tube <sup>3</sup>/<sub>4</sub> inch from the end and insert tube into nostril until the fingertips reach the nostril. Place opposite end of tube into the mouth (holding breath). Tilt head back and blow with a strong, short puff into the nostril (for very young patients, an adult should blow solution into the child's nose). Reseal dropper after use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noctiva: Do not shake. Prime before using for the first time by pumping 5 actuations into the air away from the face. Re-prime by pumping 2 actuations into the air if the product has not been used for more than 3 days. <b>Note: </b>2 sprays of 0.83 mcg/0.1 mL are not interchangeable with 1 spray of 1.66 mcg/0.1 mL; do <b>not </b>administer 2 sprays of the 0.83 mcg/0.1 mL product.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Octostim [Canadian product]: Gently blow nose to clear nasal passages. Prior to initial use, prime the pump by pressing down at least 5 times until an even spray appears. Spray is then ready for use. Dip tube inside bottle must always be submerged in the liquid when spraying. Tilt head back slightly and insert nasal applicator into one nostril. Hold breath as dose is administered. Repeat in opposite nostril if an additional spray is required. If used preoperatively, administer 2 hours prior to procedure. If spray pump is not used for 48 hours it must be primed again by pressing down a couple of times until an even spray appears. Pump will only deliver 150 mcg dose(s); if a different dose is needed, use the injection. <b>Note:</b> A test dose to measure response is recommended prior to initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stimate: Press pump down 4 times to prime prior to initial use. Once ready, tilt pump, place nozzle tip in nostril, then spray. If pump has not been used for one week it must be primed again by pressing down once or until a fine mist is present. Discard after 25 sprays (excluding priming sprays). <b>Note:</b> A test dose to measure response is recommended prior to initiating therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Diabetes insipidus: Fluid restriction should be observed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Primary nocturnal enuresis: Minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">May administer with or without food. Food may reduce/delay absorption although does not affect antidiuretic activity (Rittig 1998).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sublingual [Canadian products]: Fluid restriction should be observed. For primary nocturnal enuresis or nocturia, minimize fluid intake beginning 1 hour prior to administration and continue until the morning (for at least 8 hours).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">SubQ: Octostim [Canadian product]: May administer undiluted by direct injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157806\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Injection:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes insipidus:</b> Antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus; management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Desmopressin is ineffective for the treatment of nephrogenic diabetes insipidus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A:</b> For use in patients with hemophilia A with factor VIII coagulant activity levels &gt;5% to maintain hemostasis during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure and to also stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, or mucosal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels &le;5%, for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin with careful monitoring in patients with factor VIII levels between 2% and 5%.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nocturia (Noctiva):</b> Treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Has not been studied in patients &lt;50 years of age.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Von Willebrand disease (type 1):</b> For use in patients with mild to moderate classic von Willebrand disease (type 1) with factor VIII coagulant activity levels &gt;5% to maintain hemostasis during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure and to stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, or mucosal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Patients with von Willebrand disease who are least likely to respond are those with severe homozygous von Willebrand disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels &lt;1%; other patients may respond (variable) depending on the type of molecular defect they have. Check bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen during administration of desmopressin to ensure that adequate levels are being achieved. Not indicated for the treatment of severe classic von Willebrand disease (type I) or when there is evidence of an abnormal molecular form of factor VIII antigen.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Uremic bleeding (Octostim [Canadian product]):</b> Prevention or treatment of bleeding in patients with uremia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Intranasal:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes insipidus (DDAVP Rhinal tube):</b> Antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus; management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitation of use: Desmopressin is ineffective for the treatment of nephrogenic diabetes insipidus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hemophilia A (Stimate; Octostim [Canadian product]):</b> For use in patients with hemophilia A with factor VIII coagulant activity levels &gt;5% and to stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, or mucosal bleeding.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels &le;5%, for the treatment of hemophilia B, or in patients who have factor VIII antibodies.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>von Willebrand disease (type 1) (Stimate; Octostim [Canadian product]):</b> For use in patients with mild to moderate classic von Willebrand disease (type 1) with factor VIII coagulant activity levels &gt;5% and to stop bleeding due to spontaneous or trauma-induced injuries, such as hemarthroses, intramuscular hematomas, mucosal bleeding, or menorrhagia.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitations of use: Not indicated for the treatment of severe classic von Willebrand disease (type 1) or when there is evidence of an abnormal molecular form of factor VIII antigen.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Tablets:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diabetes insipidus:</b> Antidiuretic replacement therapy in the management of central diabetes insipidus; management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Limitation of use: Desmopressin is ineffective for the treatment of nephrogenic diabetes insipidus.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nocturia (Nocdurna [Canadian product] only): </b>Treatment of nocturia in adults with four or less nocturnal voids.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Primary nocturnal enuresis:</b> Management of primary nocturnal enuresis, either alone or as an adjunct to behavioral conditioning or other nonpharmacologic intervention.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725526\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Intracranial hemorrhage associated with certain antiplatelet agents; Surgical bleeding in patients with uremia (prevention); Uremic bleeding associated with acute or chronic renal failure</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27867242\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Desmopressin may be confused with vasopressin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Desmopressin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older for the treatment of nocturia or nocturnal polyuria due to its high risk of causing hyponatremia; safer alternatives exist (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157796\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%: Endocrine &amp; metabolic: Hyponatremia (&le;14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Hypertension (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 5%), dizziness (&le;3%), chills (&le;2%), nostril pain (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (2%), gastrointestinal disease (&le;2%), nausea (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (1% to 2%), weakness (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Abnormal lacrimation (&le;2%), conjunctivitis (&le;2%), ocular edema (&le;2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (3% to 8%), nasal discomfort (6%), nasopharyngitis (4%), nasal congestion (3%), sneezing (2% to 3%), epistaxis (&le;3%), bronchitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Decreased blood pressure, facial flushing</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal cramps, sore throat</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum transaminases (transient; associated primarily with tablets)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Burning sensation at injection site, erythema at injection site, swelling at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Abnormality in thinking, agitation, anaphylaxis (rare), balanitis, cerebral thrombosis (acute), chest pain, diarrhea, drowsiness, dyspepsia, edema, eye pruritus, hypersensitivity reaction (rare), insomnia, localized warm feeling, myocardial infarction, pain, palpitations, photophobia, tachycardia, vomiting, vulvar pain, water intoxication, weight gain (edema)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157810\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Known hypersensitivity to desmopressin or any component of the formulations; hyponatremia or a history of hyponatremia; moderate to severe renal impairment (CrCl &lt;50 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Additional product specific contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Noctiva: Polydipsia; primary nocturnal enuresis; concomitant use with loop diuretics or glucocorticoids (inhaled or systemic); syndrome of inappropriate antidiuretic hormone (SIADH) secretion (known or suspected); illnesses that may cause fluid or electrolyte imbalance (eg., gastroenteritis, salt-wasting nephropathies, systemic infection); heart failure (NYHA Class II to IV); uncontrolled hypertension.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Stimate: There are no contraindications listed in the Stimate prescribing information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Note: May not be applicable to all available dosage forms; refer to manufacturer labeling for further detail. Type 2B or platelet-type (pseudo) von Willebrand disease; habitual or psychogenic polydipsia, cardiac insufficiency or other conditions requiring diuretic therapy; nephrosis or any other condition associated with impaired water excretion, severe hepatic dysfunction; primary nocturnal enuresis; sodium losing conditions</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157793\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Allergic reactions: Severe allergic reactions have been reported with desmopressin; anaphylactic reactions have only occurred rarely with IV and intranasal administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Fluid retention: May cause fluid retention, which can worsen underlying conditions susceptible to volume status. Use with caution in patients with NYHA Class I heart failure; some products are contraindicated in NHYA Class II to IV heart failure or uncontrolled hypertension. Some products are not recommended in patients at risk for increased intracranial pressure of those with a history of urinary retention.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyponatremia: <b>[US Boxed Warning]: Noctiva: </b><b>Desmopressin can cause hyponatremia. Severe hyponatremia can be life-threatening, leading to seizures, coma, respiratory arrest, or death. Desmopressin is contraindicated in patients at increased risk of severe hyponatremia, such as patients with excessive fluid intake, illnesses that can cause fluid or electrolyte imbalances, and in those using loop diuretics or systemic or inhaled glucocorticoids. Ensure serum sodium concentrations are normal before starting or resuming desmopressin. Measure serum sodium within 7 days and ~1 month after initiating therapy or increasing the dose and periodically during treatment. More frequently monitor serum sodium in patients &ge;65 years of age and in patients at increased risk of hyponatremia. If hyponatremia occurs, desmopressin may need to be temporarily or permanently discontinued</b>. Desmopressin use may rarely lead to hyponatremia with associated signs and symptoms (eg, nausea/vomiting, headache, depressed reflexes, disorientation, irritability, muscle weakness/spasms/cramps) and extreme decreases in plasma osmolality, resulting in seizures, coma, respiratory arrest, and death. Other risk factors for hyponatremia with desmopressin use include cystic fibrosis, renal impairment, heart failure, young age, advanced age, inappropriate high fluid intake, a higher than recommended dose, and concomitant use of medications known to either increase thirst or cause syndrome of inappropriate antidiuretic hormone secretion (SIADH). Fluid restriction during use is recommended. Fluid intake in the evening and nighttime hours should be moderated to decrease the risk of hyponatremia. Monitor for signs/symptoms of hyponatremia; more frequent monitoring is recommended for patients on concomitant medications that increase the risk of hyponatremia (eg, TCAs, SSRIs, NSAIDs, chlorpromazine, carbamazepine, thiazide diuretics).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypotension: Severe hypotension may occur with rapid IV infusions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Acute cerebrovascular thrombosis and acute myocardial infarction have occurred (rare) with desmopressin injection; use with caution in patients predisposed to thrombus formation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Injection and intranasal desmopressin may cause a slight increase or transient decrease in blood pressure, and a compensatory increase in heart rate. Use with caution in patients with coronary artery insufficiency and/or hypertensive cardiovascular disease.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polydipsia (habitual or psychogenic): Use with caution in patients with habitual or psychogenic polydipsia. Patients consuming excessive amounts of water are at greater risk of hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Stress states/febrile illness: Lack of therapeutic effect has been observed in patients who have been febrile or stressed for several days; monitor for continued efficacy if indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Primary nocturnal enuresis: When using desmopressin for primary nocturnal enuresis, treatment should be interrupted if the patient experiences an acute illness (eg, fever, recurrent vomiting or diarrhea), vigorous exercise, or any condition associated with an increase in water consumption to prevent hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; von Willebrand disease type 2B: Patients with type 2B von Willebrand disease requiring hemostasis should not be treated with desmopressin since may result in platelet aggregation, thrombocytopenia, and possibly thrombosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Fluid intake should be adjusted downward in the elderly to decrease the possibility of water intoxication and hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Fluid intake should be adjusted downward in very young patients to decrease the possibility of water intoxication and hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Intranasal: Consider alternative route of administration if changes in the nasal mucosa (scarring, edema) occur leading to unreliable absorption. Some patients may demonstrate a change in response after long-term therapy (&gt;6 months) characterized as decreased response or a shorter duration of response. Discontinue in patients with concurrent nasal conditions that may increase systemic absorption of desmopressin (eg, atrophy of nasal mucosa, acute or chronic rhinitis); may resume desmopressin when conditions resolve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tablet: Patients should be instructed to restrict fluid intake from 1 hour before to 8 hours after taking desmopressin tablets. Consider alternative route of administration (IV or intranasal) with inadequate therapeutic response at maximum recommended oral doses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299137\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157798\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9330&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">CarBAMazepine: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">ChlorproMAZINE: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Nasal): May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Demeclocycline: May diminish the therapeutic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">LamoTRIgine: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lithium: May diminish the therapeutic effect of Desmopressin. Desmopressin may increase the serum concentration of Lithium.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May enhance the hyponatremic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loperamide-Loperamide Oxide: May increase the serum concentration of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Selective Serotonin Reuptake Inhibitors: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tolvaptan: May diminish the therapeutic effect of Desmopressin.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: May enhance the adverse/toxic effect of Desmopressin.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157800\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5559903\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Anecdotal reports suggest congenital anomalies and low birth weight. However, causal relationship has not been established. Desmopressin has been used safely throughout pregnancy for the treatment of diabetes insipidus (Brewster 2005; Schrier 2010). The use of desmopressin is limited for the treatment of von Willebrand disease in pregnant women (NHLBI 2007). Desmopressin is not recommended for nocturia treatment during pregnancy.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20305961\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Desmopressin is present in breast milk in small quantities. Analyses of milk from breastfeeding mothers receiving high-dose intranasal desmopressin indicate that the amount of desmopressin transferred to a breastfeeding child are considerably less than that required to influence diuresis. According to the manufacturer, the decision to breastfeed during therapy should take into account the risk of infant exposure, benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157802\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Blood pressure and pulse should be monitored during IV infusion</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Note:</b> For all indications, fluid intake, urine volume, and signs and symptoms of hyponatremia should be closely monitored especially in high-risk patient subgroups (eg, young children, elderly, patients with heart failure).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diabetes insipidus: Urine specific gravity, plasma and urine osmolality, serum electrolytes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hemophilia A: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII antigen levels, aPTT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">von Willebrand disease: Factor VIII coagulant activity, factor VIII ristocetin cofactor activity, and factor VIII von Willebrand antigen levels, bleeding time</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nocturnal enuresis: Serum electrolytes if used for &gt;7 days</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nocturia: Serum sodium concentrations at baseline, within 7 days, ~1 month after initiating/resuming therapy or increasing the dose, and periodically during therapy. More frequent monitoring in patients &ge;65 years of age and those at increased risk of hyponatremia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Uremic bleeding: Octostim [Canadian product]): Bleeding time before and 1 hour after IV infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157792\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Synthetic analogue of the antidiuretic hormone arginine vasopressin. In a dose dependent manner, desmopressin increases cyclic adenosine monophosphate (cAMP) in renal tubular cells which increases water permeability resulting in decreased urine volume and increased urine osmolality; increases plasma levels of von Willebrand factor, factor VIII, and t-PA contributing to a shortened activated partial thromboplastin time (aPTT) and bleeding time. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157809\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intranasal: Antidiuretic: 15 to 30 minutes; Increased factor VIII and von Willebrand factor (vWF) activity (dose related): 30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak effect: Antidiuretic: 1 hour; Increased factor VIII and vWF activity: 1.5 hours; Nocturia: 0.25 to 0.75 hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV infusion: Increased factor VIII and vWF activity: 30 minutes (dose related)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak effect: 1.5 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral tablet: Antidiuretic: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak effect: 4 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Intranasal, Injection, Oral tablet: ~6 to 14 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Sublingual: Rapid</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: Intranasal: ~3.5%; Oral tablet: 5% compared to intranasal, 0.16% compared to IV</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: 2 to 4 hours; Renal impairment: 9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (primarily)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157813\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Emulsion</b> (Noctiva Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.83 mcg/0.1 mL (3.8 g): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.66 mcg/0.1 mL (3.8 g): $510.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DDAVP Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg/mL (1 mL): $89.90</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DDAVP Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (5 mL): $527.23</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (DDAVP Rhinal Tube Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (2.5 mL): $299.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Desmopressin Ace Spray Refrig Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (5 mL): $246.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Desmopressin Acetate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mcg/mL (1 mL): $12.34</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Desmopressin Acetate Spray Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.01% (5 mL): $246.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Stimate Nasal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1.5 mg/mL (2.5 mL): $828.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (DDAVP Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $832.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $1,198.93</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Desmopressin Acetate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1 mg (100): $528.57</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg (100): $761.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157814\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adin (AU, NZ);</li>\n      <li>Adin Melt (AU);</li>\n      <li>Adiuretin SD (HU);</li>\n      <li>Adiuretin-SD (CZ, HN, PL);</li>\n      <li>D-VOID (IN);</li>\n      <li>DDAVP (BR, CL, IT);</li>\n      <li>DDAVP Desmopressin (PT);</li>\n      <li>Defirin (GR);</li>\n      <li>Denirin (KR);</li>\n      <li>Des-Press (LK);</li>\n      <li>Desmin (KR);</li>\n      <li>Desmogalen (DE);</li>\n      <li>Desmomelt (GB);</li>\n      <li>Desmop ODIFS Powder (KR);</li>\n      <li>Desmopresin DDAVP (AR);</li>\n      <li>Desmospray (GB, IE, PT);</li>\n      <li>Desmotab (GB, IE);</li>\n      <li>Desmotabs (DE);</li>\n      <li>Desonic (KR);</li>\n      <li>Deturine (KR);</li>\n      <li>Dinadom (AR);</li>\n      <li>Minirin (AT, AU, BG, CH, CN, CO, DE, DK, EC, EE, FI, FR, HR, HU, IL, IS, KR, LK, LT, LU, LV, MY, NO, NZ, PE, PH, PK, PT, PY, RU, SE, SG, SI, TR, TW);</li>\n      <li>Minirin DDAVP (AE, BH, CY, GR, HK, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, TH, YE);</li>\n      <li>Minirin Melt (AE, AU, CU, CY, EG, IL, KW, LB, PH, QA, SA, TH);</li>\n      <li>Minirin Nasal Spray (AU, NZ);</li>\n      <li>Minirinmelt (FR);</li>\n      <li>Minirinmelt OD (JP);</li>\n      <li>Miniryn (UA);</li>\n      <li>Minrin (BE, LU, NL);</li>\n      <li>Minurin (ES);</li>\n      <li>Nafiset (MX);</li>\n      <li>Noctisson (AE, BG, BH, EG, IQ, IR, JO, LY, OM, QA, SY, YE);</li>\n      <li>Nocutil (CH);</li>\n      <li>Nocutil Nasenspray (DE);</li>\n      <li>Octim (FR);</li>\n      <li>Octim Nasal Spray (GB);</li>\n      <li>Octostim (AE, AR, AT, AU, BH, CH, CL, CO, DE, EC, EE, EG, ES, FI, HK, HU, IL, IQ, IR, IS, KW, LT, LV, LY, MX, NL, NO, NZ, OM, QA, SE, SG, SY, YE);</li>\n      <li>Octostim Nasal Spray (KR);</li>\n      <li>Octostin (AR);</li>\n      <li>Oktostym (UA);</li>\n      <li>Ovea Odifs Powder (KR);</li>\n      <li>Pizzard (MX);</li>\n      <li>Presinex (BG, GB);</li>\n      <li>Uremin (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Apo-Desmopressin (desmopressin) tablets [product monograph]. Weston, Ontario: Apotex; July 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers Criteria for potentially inappropriate medication use in older adults [published online October 8, 2015]. <i>J Am Geriatr Soc</i>. 2015;63(11):2227-2246.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Asplund R and Aberg H, &quot;Desmopressin in Elderly Subjects With Increased Nocturnal Diuresis: A Two-Month Treatment Study,&quot; <i>Scand J Urol Nephrol</i>, 1993, 27(1):77-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/8493474/pubmed\" target=\"_blank\" id=\"8493474\">8493474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brewster UC and Hayslett JP, &quot;Diabetes Insipidus in the Third Trimester of Pregnancy,&quot; <i>Obstet Gynecol</i>, 2005, 105(5 Pt 2):1173-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/15863571/pubmed\" target=\"_blank\" id=\"15863571\">15863571</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Byrnes JJ, Larcada A, and Moake JL, &quot;Thrombosis Following Desmopressin for Uremic Bleeding,&quot; <i>Am J Hematol</i>, 1988, 28(1):63-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/3259400/pubmed\" target=\"_blank\" id=\"3259400\">3259400</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cattaneo M, &quot;Review of Clinical Experience of Desmopressin in Patients With Congenital and Acquired Bleeding Disorder,&quot; <i>Eur J Anesthesiol Suppl</i>, 1997, 14:10-4.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cheetham T and Baylis PH, &quot;Diabetes Insipidus in Children,&quot; <i>Pediatr Drugs</i>, 2002, 4(12):785-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/12431131/pubmed\" target=\"_blank\" id=\"12431131\">12431131</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chistolini A, Dragoni F, Ferrari A, et al, &quot;Intranasal DDAVP&reg;: Biological and Clinical Evaluation in Mild Factor VIII Deficiency,&quot; <i>Haemostasis</i>, 1991, 21(5):273-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/1806455/pubmed\" target=\"_blank\" id=\"1806455\">1806455</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Couch P and Stumpf JL, &quot;Management of Uremic Bleeding,&quot; <i>Clin Pharm</i>, 1990, 9(9):673-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/2171866/pubmed\" target=\"_blank\" id=\"2171866\">2171866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Das P, Carcao M, and Hitzler J, &quot;DDAVP-Induced Hyponatremia in Young Children,&quot; <i>J Pediatr Hematol Oncol</i>, 2005, 27(6):330-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/15956888/pubmed\" target=\"_blank\" id=\"15956888\">15956888</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Das P, Carcao M, and Hitzler J, &quot;Use of Recombinant Factor VIIa Prior to Lumbar Puncture in Pediatric Patients With Acute Leukemia,&quot; <i>Pediatr Blood Cancer</i>, 2006, 47(2):206-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/16007583/pubmed\" target=\"_blank\" id=\"16007583\">16007583</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dave SP, Greenstein AJ, Sachar DB, et al, &quot;Bleeding Diathesis in Amyloidosis With Renal Insufficiency Associated With Crohn's Disease: Response to Desmopressin,&quot; <i>Am J Gastroenterol</i>, 2002, 97(1):187-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/11808946/pubmed\" target=\"_blank\" id=\"11808946\">11808946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP Injection (desmopressin) injection [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP Injection (desmopressin) injection [product monograph]. North York, Ontario: Ferring; April 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP Melt (desmopressin) orally disintegrating tablets [product monograph]. North York, Ontario: Ferring; August 2006.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP Nasal Spray (desmopressin) [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP Rhinal Tube (desmopressin) spray [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DDAVP Tablets (desmopressin) tablet [prescribing information]. Parsippany, NJ: Ferring Pharmaceuticals; December 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eller N, Kollenz CJ, and Hitzenberger G, &quot;A Comparative Study of Pharmacodynamics and Bioavailability of 2 Different Desmopressin Nasal Sprays,&quot; <i>Int J Clin Pharmacol Ther</i>, 1998, 36(3):139-45.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/9562229/pubmed\" target=\"_blank\" id=\"9562229\">9562229</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eller N, Kollenz, Bauer P, et al, &quot;The Duration of Antidiuretic Response of Two Desmopressin Nasal Sprays,&quot; <i>Int J Clin Pharmacol Ther</i>, 1998, 36(9):494-500.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/9760011/pubmed\" target=\"_blank\" id=\"9760011\">9760011</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Frontera JA, Lewin JJ 3rd, Rabinstein AA, et al; Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: A Statement for Healthcare Professionals from the Neurocritical Care Society and Society of Critical Care Medicine. <i>Neurocrit Care</i>. 2016; 24(1):6-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/26714677/pubmed\" target=\"_blank\" id=\"26714677\">26714677</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lusher JM, &quot;Response to 1-Deamino-8-D-Arginine Vasopressin in von Willebrand Disease,&quot; <i>Haemostasis</i>, 1994, 24(5):276-84.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/7843638/pubmed\" target=\"_blank\" id=\"7843638\">7843638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"17538089\"></a>Mannucci PM, Levi M. Prevention and treatment of major blood loss. <i>N Engl J Med</i>. 2007;356(22):2301-2311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/17538089/pubmed\" target=\"_blank\" id=\"17538089\">17538089</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mannucci PM and Cattaneo M, &quot;Desmopressin: A Nontransfusional Treatment of Hemophilia and von Willebrand Disease,&quot; <i>Haemostasis</i>, 1992, 22(5)276-80.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6401193\"></a>Mannucci PM, Remuzzi G, Pusineri F, et al, &quot;Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia,&quot; <i>N Engl J Med</i>, 1983, 308(1):8-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/6401193/pubmed\" target=\"_blank\" id=\"6401193\">6401193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Molnar Z, Farkas V, Nemes L, et al, &quot;Hyponatraemic Seizures Resulting From Inadequate Post-Operative Fluid Intake Following a Single Dose of Desmopressin,&quot; <i>Nephrol Dial Transplant</i>, 2005, 20(10):2265-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/16014348/pubmed\" target=\"_blank\" id=\"16014348\">16014348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Heart, Lung, and Blood Institute, &ldquo;The Diagnosis, Evaluation, and Management of von Willebrand Disease,&rdquo; NIH Publication No. 08-5832. Bethesda, MD: U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Heart, Lung, and Blood, 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nocdurna (desmopressin) [product monograph]. North York, Ontario, Canada: Ferring Inc; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noctiva (desmopressin) [prescribing information]. Chesterfield, MO: Avadel Specialty Pharmaceutials LLC; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Octostim (desmopressin) [product monograph]. North York, Ontario, Canada: Ferring Inc; July 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rembratt A, Graugaard-Jensen C, Senderovitz T, et al, &quot;Pharmacokinetics and Pharmacodynamics of Desmopressin Administered Orally Versus Intravenously at Daytime Versus Night-Time in Healthy Men Aged 55-70 Years,&quot; <i>Eur J Clin Pharmacol</i>, 2004, 60(6):397-402.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/15197520/pubmed\" target=\"_blank\" id=\"15197520\">15197520</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rembratt A, Riis A, and Norgaard JP, &quot;Desmopressin Treatment in Nocturia; An Analysis of Risk Factors for Hyponatremia,&quot; <i>Neurourol Urodyn</i>, 2005, 25(2):105-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/16304673/pubmed\" target=\"_blank\" id=\"16304673\">16304673</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Richardson DW and Robinson AG, &quot;Desmopressin,&quot; <i>Ann Intern Med</i>, 1985, 103(2):228-39.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/3893256/pubmed\" target=\"_blank\" id=\"3893256\">3893256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robson WL, Leung AK, and Norgaard JP, &quot;The Comparative Safety of Oral Versus Intranasal Desmopressin for the Treatment of Children With Nocturnal Enuresis,&quot; <i>J Urol</i>, 2007, 178(1):24-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/17574054/pubmed\" target=\"_blank\" id=\"17574054\">17574054</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rittig S, Jensen AR, Jensen KT, et al. Effect of food intake on the pharmacokinetics and antidiuretic activity of oral desmopressin (DDAVP) in hydrated normal subjects. <i>Clin Endocrinol (Oxf)</i>. 1998;48(2):235-241.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/9579238/pubmed\" target=\"_blank\" id=\"9579238\">9579238</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schrier RW, &quot;Systemic Arterial Vasodilation, Vasopressin, and Vasopressinase in Pregnancy,&quot; <i>J Am Soc Nephrol</i>, 2010, 21(4):570-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/19959721/pubmed\" target=\"_blank\" id=\"19959721\">19959721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith TJ, Gill JC, Ambruso DR, et al, &quot;Hyponatremia and Seizures in Young Children given DDAVP,&quot; <i>Am J Hematol</i>, 1989, 31(3):199-202.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/2500851/pubmed\" target=\"_blank\" id=\"2500851\">2500851</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stenberg A and L&auml;ckgren G, &quot;Desmopressin Tablets in the Treatment of Severe Nocturnal Enuresis in Adolescents,&quot; <i>Pediatrics</i>, 1994, 94(6 Pt 1):841-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/7970999/pubmed\" target=\"_blank\" id=\"7970999\">7970999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stimate (desmopressin acetate) nasal spray [prescribing information]. King of Prussia, PA: CSL Behring; June 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thumfart J, Roehr CC, Kapelari K, et al, &quot;Desmopressin Associated Symptomatic Hyponatremic Hypervolemia in Children. Are There Predictive Factors?&quot; <i>J Urol</i>, 2005, 174(1):294-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/15947670/pubmed\" target=\"_blank\" id=\"15947670\">15947670</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"6731500\"></a>Watson AJ and Keogh JA., &quot;1-Deamino-8-D-Arginine Vasopressin as a Therapy for the Bleeding Diathesis of Renal Failure,&quot; <i>Am J Nephrol</i>, 1984a, 4(1):49-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/6731500/pubmed\" target=\"_blank\" id=\"6731500\">6731500</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watson AJ and Keogh JA, &quot;1-Deamino-8-d-Arginine Vasopressin (DDAVP): A Potential New Treatment for the Bleeding Diathesis of Acute Renal Failure,&quot; <i>Pharmatherapeutica</i>, 1984, 3(9):618-22.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/6728864/pubmed\" target=\"_blank\" id=\"6728864\">6728864</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weinstein RE, Bona RD, Altman AJ, et al, &quot;Severe Hyponatremia after Repeated Intravenous Administration of Desmopressin,&quot; <i>Am J Hematol</i>, 1989, 32(4):258-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/desmopressin-drug-information/abstract-text/2816922/pubmed\" target=\"_blank\" id=\"2816922\">2816922</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9330 Version 195.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F51112251\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F157823\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F157824\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F157868\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F157828\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F157850\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F157829\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F2697324\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15796022\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F157804\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F157789\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F21005940\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F6705371\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F157807\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F157806\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725526\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27867242\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157796\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F157810\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F157793\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299137\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F157798\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F157800\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F5559903\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20305961\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F157802\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F157792\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F157809\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F157813\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F157814\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9330|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=desmopressin-patient-drug-information\" class=\"drug drug_patient\">Desmopressin: Patient drug information</a></li><li><a href=\"topic.htm?path=desmopressin-pediatric-drug-information\" class=\"drug drug_pediatric\">Desmopressin: Pediatric drug information</a></li></ul></div></div>","javascript":null}